Axcynsis Therapeutics' AT03-65 Receives FDA IND Clearance for CLDN6-Targeting ADC
• Axcynsis Therapeutics received FDA clearance for its IND application for AT03-65, a differentiated CLDN6-targeting antibody-drug conjugate (ADC).
• AT03-65 leverages Axcynsis' AxcynDOT™ technology for precise drug delivery to tumors expressing CLDN6, a target in various cancers.
• This regulatory milestone enables Axcynsis to advance AT03-65 into clinical trials, marking a significant step in developing novel cancer therapies.
• The ADC is designed to improve efficacy and reduce systemic toxicity compared to traditional chemotherapy, addressing unmet needs in oncology.
© Copyright 2025. All Rights Reserved by MedPath